Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma

Anosys60 enrolled

Overview

The objective is to determine the safety and efficacy of dexosome immunotherapy in patients with Stage IV malignant melanoma

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Melanoma

Interventions

autologous dexosomes loaded with tumor-specific peptidesBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

* Patients with Stage IV metastatic melanoma with 0-1 prior treatments for metastatic disease. * All patients must have distant skin, subcutaneous, or nodal metastases (M1a) or lung metastases (M1b), measurable disease, normal lactate dehydrogenase levels, and HLA type A1, A2, or B35. * Patients must have adequate organ function and an estimated life expectancy of at least 3 months.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.